RESUMEN
Short-chain quinones have been investigated as therapeutic molecules due to their ability to modulate cellular redox reactions, mitochondrial electron transfer and oxidative stress, which are pathologically altered in many mitochondrial and neuromuscular disorders. Recently, we and others described that certain short-chain quinones are able to bypass a deficiency in complex I by shuttling electrons directly from the cytoplasm to complex III of the mitochondrial respiratory chain to produce ATP. Although this energy rescue activity is highly interesting for the therapy of disorders associated with complex I dysfunction, no structure-activity-relationship has been reported for short-chain quinones so far. Using a panel of 70 quinones, we observed that the capacity for this cellular energy rescue as well as their effect on lipid peroxidation was influenced more by the physicochemical properties (in particular logD) of the whole molecule than the quinone moiety itself. Thus, the observed correlations allow us to explain the differential biological activities and therapeutic potential of short-chain quinones for the therapy of disorders associated with mitochondrial complex I dysfunction and/or oxidative stress.
Asunto(s)
Adenosina Trifosfato/metabolismo , Antioxidantes/química , Antioxidantes/farmacología , Enfermedades Mitocondriales/metabolismo , Ubiquinona/análogos & derivados , Animales , Línea Celular , Fenómenos Químicos/efectos de los fármacos , Complejo I de Transporte de Electrón/deficiencia , Complejo I de Transporte de Electrón/metabolismo , Humanos , Peroxidación de Lípido/efectos de los fármacos , Ratas , Ubiquinona/química , Ubiquinona/farmacologíaRESUMEN
For a series of beta-homophenylalanine based inhibitors of dipeptidyl peptidase IV ADME properties were improved by the incorporation of amide replacements. These efforts led to a novel series of potent and selective inhibitors of DPP-4 that exhibit an attractive pharmacokinetic profile and show excellent efficacy in an animal model of diabetes.
Asunto(s)
Amidas/química , Aminobutiratos/química , Inhibidores de la Dipeptidil-Peptidasa IV , Relación Estructura-Actividad , Amidas/antagonistas & inhibidores , Células CACO-2 , Línea Celular Tumoral , Química Farmacéutica , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Inhibidores de la Dipeptidil-Peptidasa IV/uso terapéutico , Diseño de Fármacos , Humanos , Hipoglucemiantes/antagonistas & inhibidores , Hipoglucemiantes/uso terapéutico , Inhibidores de Proteasas/farmacocinética , Inhibidores de Proteasas/farmacología , Canales de Sodio/metabolismoRESUMEN
A series of highly potent and selective inhibitors of DPP-4 was optimized for ADMET properties. The effort resulted in the discovery of inhibitor 1g, that exhibits excellent efficacy in an oral glucose tolerance test and an attractive pharmacokinetic profile.
